MSD's Keytruda succeeded in applying Hodgkin's lymphoma benefit for the second time as an immuno-cancer drug. Takeda is considered the best option for Hodgkin's lymphoma treatment. It is evaluated as suitable as a new option by proving superiority through comparative clinical trials with Takeda's Adcetris.

As of March 1, Keytruda was reimbursed as a second or more treatment if it recurred or progressed after self-hematopoietic stem cell transplantation (ASCT) in typical Hodgkin lymphoma, and a third or more treatment if self-hematopoietic stem cell transplantation is impossible. Yoon Deok-hyun, a professor of oncology at Asan Medical Center in Seoul, commented on the expansion of the benefit, "Keytruda sho